Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children

Journal of Neural Transmission

Volumn 120, Issue 7, 2013, Pages 1127-1133

  Yang, Li ^a   Qian, Qiujin ^a   Liu, Lu ^a   Li, Haimei ^a   Faraone, Stephen V ^b   Wang, Yufeng ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Adrenergic; Atomoxetine; Attention deficit hyperactivity disorder; Gene

Indexed keywords

ATOMOXETINE; ADRA1A PROTEIN, HUMAN; ADRA2A PROTEIN, HUMAN; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; NORADRENALIN TRANSPORTER; PROPYLAMINE;

ADOLESCENT; ADRENERGIC TRANSMISSION; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG DOSE TITRATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR GENE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOSE RESPONSE; GENE FREQUENCY; GENETICS; PHARMACOGENETICS;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPYLAMINES; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 84879555010     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0955-z     Document Type: Article

References (38)

1. Andrews GD, Lavin A (2006) Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology 31(3):8
2. Arnsten AF, Li BM (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 57(11):1377-1384. doi: 10.1016/j.biopsych.2004.08.019
3. Arnsten AF, Steere JC, Hunt RD (1996) The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53(5):448-455
4. Barkley RA (1998) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd edn. Guilford Press, New York
5. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366(9481):237-248. doi: 10.1016/S0140-6736(05)66915-2
6. Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46(9):1234-1242
7. Biederman J, Spencer TJ (2000) Genetics of childhood disorders: XIX. ADHD, Part 3: is ADHD a noradrenergic disorder? J Am Acad Child Adolesc Psychiatry 39(10):1330-1333
8. Cho SC, Kim JW, Kim HW, Kim BN, Shin MS, Cho DY, Jung SW, Chung US, Son JW (2011) Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype. Psychiatr Genet 21(3):132-135. doi: 10.1097/YPG.0b013e328341a389
9. Comings DE, Gade-Andavolu R, Gonzalez N, Blake H, Wu S, MacMurray JP (1999) Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin Genet 55(3):160-172
10. Deupree JD, Smith SD, Kratochvil CJ, Bohac D, Ellis CR, Polaha J, Bylund DB, Team UCAR (2006) Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies. Am J Med Genet Part B Neuropsychiatr Genet 141B(8):877-884. doi: 10.1002/ajmg.b.30371
11. Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD (2011) Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment health 5:14. doi: 10.1186/1753-2000-5-14
12. DuPaul GJ (1998) ADHD rating scale-IV: checklists, norms, and clinical interpretation. Guilford Press, New York
13. Elia J, Capasso M, Zaheer Z, Lantieri F, Ambrosini P, Berrettini W, Devoto M, Hakonarson H (2009) Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A. Psychiatr Genet 19(3):134-141. doi: 10.1097/YPG.0b013e32832a5043
14. Faraone SV, Mick E (2010) Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 33(1):159-180. doi: 10.1016/j.psc.2009.12.004
15. Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2(2):104-113
16. Franowicz JS, Arnsten AF (1998) The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology 136(1):8-14
17. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114(1):e1-e8
18. Kiive E, Kurrikoff T, Maestu J, Harro J (2010) Effect of alpha2A-adrenoceptor C-1291G genotype and maltreatment on hyperactivity and inattention in adolescents. Prog Neuropsychopharmacol Biol Psychiatry 34(1):219-224. doi: 10.1016/j.pnpbp.2009.11.011
19. Kim CH, Kim HS, Cubells JF, Kim KS (1999) A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 274(10):6507-6518
20. Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV (2008) Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Mol Psychiatry 13(6):624-630. doi: 10.1038/sj.mp.4002090
21. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159(11):1896-1901
22. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22(2):389-395
23. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165(6):721-730. doi: 10.1176/appi.ajp.2007.05091676
24. Park L, Nigg JT, Waldman ID, Nummy KA, Huang-Pollock C, Rappley M, Friderici KH (2005) Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry 10(6):572-580. doi: 10.1038/sj.mp.4001605
25. Ramoz N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, Allen AJ, Hamon M, Purper-Ouakil D, Gorwood P (2009) A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 34(9):2135-2142. doi: 10.1038/npp.2009.39
26. Retz W, Rosler M, Kissling C, Wiemann S, Hunnerkopf R, Coogan A, Thome J, Freitag C (2008) Norepinephrine transporter and catecholamine-O- methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm 115(2):323-329. doi: 10.1007/s00702-007- 0822-5
27. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH (2003) Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet Part B Neuropsychiatr Genet 120B(1):116-120. doi: 10.1002/ajmg.b.20018
28. Roman T, Polanczyk GV, Zeni C, Genro JP, Rohde LA, Hutz MH (2006) Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. Mol Psychiatry 11(1):8-10. doi: 10.1038/sj.mp.4001743
29. Schmitz M, Denardin D, Silva TL, Pianca T, Roman T, Hutz MH, Faraone SV, Rohde LA (2006) Association between alpha-2a-adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry 60(10):1028-1033. doi: 10.1016/j.biopsych. 2006.02.035
30. Sengupta SM, Grizenko N, Thakur GA, Bellingham J, DeGuzman R, Robinson S, TerStepanian M, Poloskia A, Shaheen SM, Fortier ME, Choudhry Z, Joober R (2012) Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatr Neurosci 37(2):129-137. doi: 10.1503/jpn.110073
31. Solanto MV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94(1):127-152
32. Steele M, Jensen PS, Quinn DM (2006) Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28(11):1892-1908. doi: 10.1016/j.clinthera.2006.11.006
33. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH (2003) A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112(5):e404
34. Stevenson J, Langley K, Pay H, Payton A, Worthington J, Ollier W, Thapar A (2005) Attention deficit hyperactivity disorder with reading disabilities: preliminary genetic findings on the involvement of the ADRA2A gene. J Child Psychol Psychiatry 46(10):1081-1088. doi: 10.1111/j.1469-7610.2005.01533.x
35. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M (2001) Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40(2):168-179. doi: 10.1097/00004583-200102000-00011
36. Wang B, Wang Y, Zhou R, Li J, Qian Q, Yang L, Guan L, Faraone SV (2006) Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of attention-deficit/hyperactivity disorder. Am J Med Genet Part B Neuropsychiatr Genet 141B(2):130-134. doi: 10.1002/ajmg.b.30258
37. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 41(3):222-230. doi: 10.1080/00048670601057767
38. Yang L, Wang YF, Li J, Faraone SV (2004) Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43(9):1154-1158. doi: 10.1097/01.chi.0000131134.63368.46